CAR-T Therapy for Primary central nervous system Lymphoma at Sheba Medical Center

• العلاج بالخلايا التائية ذات مستقبل المستضد الخيمري
• فحص دم
• فحص كيمياء الدم
• خزعة
• التصوير المقطعي المحوسب
• استشارة طبيب
• استشارة طبيب أورام
• استشارة طبيب أمراض دم
• استشارة جراح
• استشارة طبيب أعصاب
• استشارة طبيب الأشعة
• تعداد الدم الكامل مع كشف أوسام الأورام السرطانية بالإضافة إلى تحليل البروتينات
• تصوير الأوعية المقطعي
• تخطيط كهربية القلب
• تصوير بالرنين المغناطيسي للرأس
• الرعاية ما بعد الجراحة
• فحوصات ما قبل العملية الجراحية
• تصوير مقطعي بالإصدار البوزيتروني
• استشارة طبيب سرطان الدم
• خدمات التمريض على مدار الساعة
• ثلاث وجبات يومية من إعداد أخصائي التغذية

• 21 ايام في المستشفى

• نقل المطار والعيادة والمطار

CAR-T Therapy for Primary CNS Lymphoma at Sheba Medical Center

For patients diagnosed with Primary central nervous system Lymphoma (PCNSL), a rare and complex cancer affecting the brain and central nervous system, choosing the right treatment center is critical.
Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease.

Sheba combines cutting-edge immunotherapy with deep expertise in neuro-oncology, delivering highly personalized care for even the most challenging cases.

A Faster Path to Advanced Treatment

At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality crucial for patients with aggressive CNS disease.

• Apheresis – collection of the patient’s T-cells
• Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
• Infusion – reintroduction of modified cells designed to target lymphoma cells, including those within the central nervous system

By avoiding external laboratories, treatment can begin in approximately 10 days, significantly reducing delays and allowing faster access to life-saving therapy.
CAR-T acts as a “living therapy,” continuing to work inside the body and offering the potential for long-term disease control and remission.
All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology.

Proven Expertise in Complex Cases

Primary CNS lymphoma requires a highly specialized, multidisciplinary approach. At Sheba, hematologists, neuro-oncologists, neurologists, and imaging specialists work together to design the most effective treatment strategy for each patient.
CAR-T therapy offers a promising option for patients who have exhausted conventional treatments, with encouraging remission outcomes even in advanced cases.

Why Patients Choose Sheba

• Rapid access to CAR-T therapy – treatment initiation in ~10 days
• Extensive experience – leading CAR-T program in the region
• Dedicated CAR-T units – with 24/7 expert monitoring
• Multidisciplinary CNS expertise – integrated hematology and neuro-oncology care
• Full international support – medical review, travel coordination, and patient assistance

Comprehensive, Personalized Care

Each patient undergoes a full evaluation, including advanced brain imaging (MRI/CT), molecular and genetic testing, and complete medical assessment, ensuring a precise and individualized treatment plan.
Services are available in English, Russian, and Arabic, providing a smooth and supportive experience for international patients.

A Leading Center for Advanced Neuro-Oncology Care

By combining innovative CAR-T technology, in-house cell production, and multidisciplinary expertise, Sheba offers one of the most advanced treatment options for Primary CNS Lymphoma worldwide giving patients access to therapies that can extend survival and improve quality of life.

• منسق طبي خاص
• ترتيبات السفر الطبي - حجز تذاكر السفر الجوي وغرف الفنادق بأسعار خاصة للشركاء
• دعوة المريض أثناء السفر الطبي